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Human immunodeficiency virus type 1 subtype C (HIV-1C) accounts for about 50% of all HIV infections in the pandemic and is the
predominant subtype in the heavily burdened region of southern Africa. HIV-1C possesses unique genetic and phenotypic features that might be
associated with biological differences compared to other subtypes. Here, we generated virus isolates from individuals at different stages of HIV-1C
infection and investigated the chemokine receptor repertoire that the derived HIV-1C isolates may utilize for entry. Our results show that the R5
phenotype predominates among viruses in Botswana, with a lesser contribution of viruses showing the dualtropic X4R5 phenotype. No viruses of
pure X4 phenotype were found, which suggests no discernable evolution of HIV-1C to a monotropic X4 phenotype as the epidemic ages in
Botswana. Usage of other coreceptors was rare and apparently insignificant. These results enhance our understanding of HIV-1C biology, with
implications for designing and testing therapeutic and prophylactic agents.
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In most countries in southern Africa, HIV-1 prevalence rates
exceed 20% in the adult population (UNAIDS, 2002). HIV-1C
is the predominant HIV-1 genotype in southern Africa
(Novitsky et al., 2002; Ping et al., 1999; Williamson et al.,
2003), and the epidemic in this region is characterized by a
relatively high level of intrasubtype diversity (Choudhury et
al., 2000; Novitsky et al., 1999; van Harmelen et al., 2001).
HIV-1C is also the predominant and most rapidly spreading
HIV-1 subtype in the world (Esparza and Bhamarapravati,
2000; Essex, 1999; Osmanov et al., 2002). Comparative studies0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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pathogenesis have been difficult to undertake because there are
few regions where multiple subtypes coexist at sufficiently
high levels to allow informative population-based studies.
However, in east Africa, where subtypes A, C, D, and their
recombinants co-circulate at relatively high levels, some
studies have suggested significant differences between subtype
C and other subtypes. In Kenya, a cross-sectional study showed
that women infected with HIV-1C had significantly lower CD4
cell counts and higher plasma RNA levels than those infected
with subtypes A or D (Neilson et al., 1999).
It has also been reported that, in Tanzania, HIV-1C appears
to have been introduced after subtypes A and D were already
established and HIV-1C quickly became one of the major
subtypes while subtype D appears to have declined in Dar es
Salaam (Renjifo et al., 1998). In a mother-to-child transmission
cohort, it was observed that mothers infected with subtype C
and intersubtype recombinants were significantly more likely6) 247 – 260
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with subtype D viruses (Blackard et al., 2001; Renjifo et al.,
2001). In addition, HIV-1C showed preferential transmission in
utero when compared to HIV-1A or HIV-1D in the same cohort
(Renjifo et al., 2004). Furthermore, in A–D and C–D
recombinant genomes, the V3 region of subtype A or C was
preferentially selected, suggesting reduced fitness of subtype D
V3 with respect to V3 from subtype A or C (Renjifo et al.,
1999). These epidemiological and observational studies pro-
vide clues to subtype-specific differences and suggest that HIV-
1C in particular may be unique in its spread and natural history,
but they fail to provide answers to the mechanisms that may
underlie the differences.
Virological factors may be at least partially responsible for
the rapid expansion and predominance of HIV-1C in southern
Africa and elsewhere. Studies have shown, for example, that
HIV-1C in Africa usually possesses an extra copy of the NF-nB
enhancer element in the long terminal repeat (LTR) region (Gao
et al., 1996; Montano et al., 1997; Salminen et al., 1996), which
may be associated with an increased responsiveness to activation
by cellular proteins and proinflammatory cytokines (Jeeninga et
al., 2000; Montano et al., 1997, 2000; Naghavi et al., 1999). In
addition, utilization of coreceptors other than CCR5 is rare for
HIV-1C (Bjorndal et al., 1999; Cecilia et al., 2000; Tscherning et
al., 1998), although the implications of this observation on
transmission and pathogenesis of HIV-1C remain undetermined.
The observation that HIV-1C viruses predominantly use CCR5
(R5 phenotype) as the major coreceptor for entry into cells even
in late stages of disease is intriguing because, in approximately
50% of HIV-1 subtype B infections, progression to AIDS is
associated with development of viral variants that utilize
CXCR4 (X4 phenotype) as coreceptor (Kuiken et al., 1992;
Schuitemaker et al., 1992; Tersmette et al., 1989a). This change
in viral phenotype from R5 to X4 has also been frequently
observed for other major non-B HIV subtypes and recombinants
(Bjorndal et al., 1997; De Wolf et al., 1994; Kato et al., 1999;
Tscherning et al., 1998; Vergne et al., 2003), suggesting that
HIV-1C is unique in maintaining its predominant CCR5 tropism
throughout infection.
Early studies showed that HIV-1C viruses display low-level
replication kinetics in macrophages followed by a nonproduc-
tive stage from which virus could be rescued by co-cultivation
with Jurkattat cells (Bjorndal et al., 1999). Recently, it has been
suggested that CCR5-tropic HIV-1C viruses have an attenuated
phenotype compared to their subtype B counterparts when
propagated in CD4+ lymphocytes and macrophages (Ball et al.,
2003; Pollakis et al., 2004). These studies further show that the
restriction to virus replication observed for HIV-1C viruses is at
the level of virus entry via the CCR5 coreceptor. The in vitro
studies suggest uniqueness of HIV-1C in the global epidemic
and have led to speculation that the apparent attenuation of
HIV-1C may be responsible for its success as the predominant
subtype in the pandemic.
In earlier studies in Botswana, we demonstrated that non-
recombinant HIV-1C is the predominant genotype, and we have
undertaken detailed phylogenetic analysis and have identified
various intrasubtype lineages based on near full-length genomeanalysis of HIV-1C (Novitsky et al., 1999, 2002). We have
generated infectious and non-infectious clones of the virus to
facilitate detailed genetic analysis (Ndung’u et al., 2000, 2001).
However, while genotypic data are clearly important in tracking
the changing population dynamics of an epidemic as well as in
designing appropriate therapeutic and prophylactic interven-
tions, it is not always possible to predict viral phenotype from
genotypic data. In the present study, therefore, we sought to
study the efficiency of generating viral isolates and the extent of
coreceptor usage by primary viral isolates from individuals at
different stages of infection, all assessed in relation to clinical
staging or CD4 cell count. Specifically, we addressed whether
there is a trend towards CXCR4-only or other coreceptor
tropism for HIV-1C isolates from Botswana as the epidemic
matures, in light of a number of recent reports suggesting such a
trend in other countries (Cilliers et al., 2003; Johnston et al.,
2003; Papathanasopoulos et al., 2002; van Rensburg et al.,
2002). We analyzed subtype C viruses isolated from Botswana
in 1996 and in 2003. We reasoned that, if there is a changing
coreceptor usage profile for HIV-1C, isolates from later years
might show a greater tendency towards CXCR4-tropism,
assuming similar stages of disease progression. We also
assessed the reliability of V3 loop sequence-based methods in
predicting coreceptor usage for HIV-1C.
Results
Samples
The 1996 samples described here were from anonymous
donors from Botswana, and details on HIV testing, sample
collection, peripheral blood mononuclear cell (PBMC) isola-
tion, and the relevant study information were described
previously (Ndung’u et al., 2000; Novitsky et al., 2001). At
the time, CD4+ cell count and viral load quantification were
not available in Botswana. Age, gender, clinical manifestation,
and disease staging information were available. Patient clinical
classification was carried out according to the 1987 Centers for
Disease Control and Prevention (CDC) revised criteria (CDC,
1987). The 1996 viral isolates were propagated in PBMCs from
anonymous HIV-negative donors from North America (as
opposed to the 2003 samples where PBMCs from Botswana
blood donors were used). Details on viral load, CD4 cell count,
viral isolation, and envelope gene sequencing are summarized
in Table 1.
HIV-1C isolation
Eleven viruses were isolated from PBMC obtained from two
asymptomatic and nine symptomatic HIV-1-positive donors in
Botswana in 1996 (Novitsky et al., 1999, 2002). For the 2003
samples, viral isolation was attempted from PBMC or plasma
from forty-two HIV-infected individuals. The CD4 cell count
for this study population ranged from 10 to 1047 cells/Al with a
mean of 220 and a median of 166. Twenty-eight of the forty-
two (66.7%) PBMC source individuals had CD4 cell counts
less than 200 cells/Al, indicating that they were in late stages of
Table 1
Summary of CD4 cell counts and viral load for the 2003 samples tested for virus isolationa
Sample ID CD4 cell count
(cells/Al)
Viral load
(RNA copies/ml)
Viral isolate
obtained
Source of
sequence
Envelope sequence
available
03BW.0824 170 74,500 No PBMC Yes
03BW.0856 168 <400 Yes PBMC Yes
03BW.0868 153 <400 Yes PBMC Yes
03BW.0893 149 <400 Yes – No
03BW.0900 179 <400 Yes PBMC Yes
03BW.0949 334 510,000 Yes PBMC Yes
03BW.1008* 33 >750,000 No Plasma Yes
03BW.1017* 94 125,000 No Plasma Yes
03BW.1025 173 >750,000 Yes – No
03BW.1042 38 >750,000 No PBMC Yes
03BW.1048 22 705,000 No PBMC Yes
03BW.1054* 80 131,000 No Plasma Yes
03BW.1065 33 >750,000 Yes PBMC Yes
03BW.1075 167 >750,000 Yes PBMC Yes
03BW.1078* 143 35,900 Yes Plasma Yes
03BW.1081* 134 193,000 Yes Plasma Yes
03BW.1088 112 139,000 Yes PBMC Yes
03BW.1091 153 250,000 Yes PBMC Yes
03BW.1101 134 193,000 Yes PBMC Yes
03BW.1102 10 >750,000 Yes PBMC Yes
03BW.1103 176 99,800 Yes PBMC Yes
03BW.1105 23 >750,000 Yes Co-culture Yes
03BW.1110 49 >750,000 Yes PBMC Yes
03BW.1133 ND 125,000 Yes PBMC Yes
03BW.1718 219 100,000 Yes PBMC Yes
03BW.1787 166 43,700 Yes PBMC Yes
03BW.1790 112 25,200 Yes – No
03BW.1796 142 >750,000 Yes PBMC Yes
03BW.4432 450 189,000 No PBMC Yes
03BW.4437 400 45,400 Yes PBMC Yes
03BW.4473 211 109,000 Yes PBMC Yes
03BW.4482 103 >750,000 Yes PBMC Yes
03BW.4490 652 1320 No – No
03BW.4499 881 7050 No PBMC Yes
03BW.6063 227 713,000 Yes PBMC Yes
03BW.6218 1047 4750 Yes PBMC Yes
03BW.6270 77 740,000 Yes PBMC Yes
03BW.6274 351 120,000 Yes PBMC Yes
03BW.6351 311 56,000 No Co-culture Yes
03BW.6360 171 7070 No PBMC Yes
03BW.6364 314 26,200 No Co-culture Yes
03BW.6450 448 37,900 No PBMC Yes
a In a few cases, isolates could not be generated from source PBMCs and were obtained from plasma (shown with asterisks) or PMBC co-cultures. In 4 cases, the
envelope sequences were not obtained because of an insufficient amount of available DNA.
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to greater than 5.9 with a median of 5.1 and a mean of 4.9. Four
study participants had undetectable HIV-1 viral load despite
relatively low CD4 cell count, which is not an uncommon
observation in Botswana. Of the 42 samples analyzed, 29
yielded viral isolates, representing an isolation success rate of
69%. Twenty-one isolates were generated from the 28 samples
with CD4 count less than 200, representing an isolation success
rate of 75%, while 7 isolates were obtained from the 13
samples with CD4 cell count above 200, which is equivalent to
a success rate of 53.8%. CD4 cell count was unavailable for 1
sample from which an isolate was obtained. A chi-square test
was used to assess whether the ability to isolate the virus is
associated with the level of CD4 cell count. For this purpose,
CD4 count equal to or less than 200 was considered low, whileCD4 count greater than 200 was considered high. Isolation was
not associated with the CD4 level (chi-square = 1.83, P = 0.18;
Fisher’s Exact P = 0.28).
The growth characteristics in PBMCs for the viruses detected
in the 2003 samples are summarized in Table 2. Statistical tests
were done to examine differences between the CD4 cell counts,
viral load, and the growth pattern in vitro of the samples as
described in Tables 2 and 3. There was a significant negative
linear relation between CD4 and plasma viral load (Spearman
rank order correlation, rs = 0.54126; P < 0.001).
Determination of coreceptor usage
Although several studies have suggested that HIV-1C viruses
may be unique in that variants that use coreceptors other than
Table 2
HIV-1C isolates’ replication in donor PBMCsa
Sample ID p24 antigen (pg/ml) in culture supernatant
Day 1 Day 4 Day 7 Day 10 Day 14
03BW.0856 0 18 176 817 6010
03BW.0868 0 0 61 711 4023
03BW.0893 0 4 26 600 1925
03BW.0900 0 135 299 7520 6478
03BW.0949 0 50 1276 6394 19,133
03BW.1025 0 36 90 530 4
03BW.1065 0 220 252 799 1122
03BW.1075 0 109 1611 7818 23,352
03BW.1078 0 0 57 247 1327
03BW.1081 0 17 44 82 494
03BW.1088 0 24 33 209 754
03BW.1091 0 11 72 383 2625
03BW.1101 0 17 44 82 494
03BW.1102 0 29 675 9917 19,676
03BW.1103 0 42 54 312 1995
03BW.1105 0 123 97 333 449
03BW.1110 0 60 32 58,856 44,261
03BW.1133 0 16 194 1348 8223
03BW.1718 0 6 44 96 5477
03BW.1787 0 15 220 5214 112,780
03BW.1790 0 0 52 866 49,270
03BW.1796 0 23 475 7260 89,190
03BW.4437 0 0 74 7520 11,874
03BW.4473 0 0 47 3353 15,994
03BW.4482 0 0 25 440 5394
03BW.6063 0 13 135 3870 22,071
03BW.6218 0 15 122 454 90,440
03BW.6270 0 74 1805 7186 64,686
03BW.6274 0 89 1373 87,086 95,002
a 5  106 PBMCs from three donors were mixed and stimulated with PHA
and IL-2 for 72 h prior to co-culture with 2  106 HIV-1-infected PBMCs. The
CCR5-utilizing molecular clones MJ4 and HXB2RU3CI, and the CXCR4-
tropic HXB2RU3 were used as controls. All infections were followed by
quantification of the p24 antigen by ELISA. For the controls, culture
supernatant corresponding to 500 pg of p24 was used to infect 2  106 cells.
The following day, the target cells were washed three times with PBS and then
new media was added.
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suggested that CXCR4 utilizing variants are being encountered
with greater frequency as the epidemic matures (Cilliers et al.,
2003; Johnston et al., 2003; Papathanasopoulos et al., 2002; van
Rensburg et al., 2002). CCR5 and CXCR4 are the main
chemokine receptors utilized by most primary isolates of HIV-1
as coreceptors for cell entry, but some viral variants may use
other coreceptors. Most studies have only investigated the
ability of HIV-1C to use CXCR4 and CCR5, but we also asked
whether HIV-1C may evolve to use some of the minor
coreceptors. We therefore decided to characterize the isolated
subtype C viruses for the use of common chemokine receptors.
We also compared the isolates from 1996 to those from 2003 to
examine if there are discernable changes in coreceptor usage
profile as the HIV-1C epidemic has aged in Botswana. In order
to determine what coreceptors each of the viral isolates used to
enter cells, U87.CD4 glioma cells expressing different cor-
eceptors were infected with cell-free PBMC tissue culture
supernatants. Table 3 shows the highest amounts of p24 antigen
reached by the isolates over a 10-day culture period in U87.CD4glioma cells expressing CCR1, CCR2(b), CCR3, CXCR4, or
CCR5. All twenty-nine of the viruses studied from 1996 and
2003 that grew in any of these cells used CCR5 as a coreceptor
for entry into cells. Two isolates (03BW6218 and 03BW4482)
did not utilize any of the coreceptors tested and may require
further investigation. Three viral isolates, 96BW17A09 from
1996 and 03BW.1102 and 03BW.1110 from 2003, used CXCR4
more efficiently than they did CCR5. None of the studied
viruses used coreceptors other than CCR5 and CXCR4.
Six isolates, 96BW.0502, 96BW.1210, 96BWMO1.5,
96BWMO3.2, 03BW.6274, and 03BW.6360, appeared to use
CXCR4, but with much less efficiency than they used CCR5
because they yielded more than 100 pg/ml of p24 antigen in
U87.CD4.CXCR4 cell supernatant when propagated in these
cells (Table 3). In order to confirm whether these isolates were
truly dualtropic and in order to amplify replication of possible
minor CXCR4-tropic variants within the isolates, we undertook
two separate investigations. First, we passaged these six viral
isolates and the three that used CXCR4 better than CCR5
(96BW17A09, 03BW.1102, and 03BW.1110) in U87.CD4.
CXCR4 cells three times (data not shown). While isolates
96BW17A09, 03BW.1102, and 03BW.1110 showed robust
replication at each passage, none of the other isolates
replicated, and viral DNA could be amplified from third-
passage cells for only the three isolates. Secondly, supernatants
from all viral isolates were used to infect MT-2 cells, and the
cells were checked for viral growth by monitoring syncytia
induction and p24 antigen quantification in tissue culture
fluid. Again, only isolates 96BW17A09, 03BW.1102, and
03BW.1110 showed extensive syncytia induction and p24
antigen production (data not shown). Isolate 03BW.6274
showed mild syncytia induction and low-level replication in
MT-2 cells.
Genotypic analysis of env gene of HIV isolates
Our previous studies in Botswana have shown that HIV-1C
viruses, which can be assigned to diverse phylogenetic
lineages, dominate the HIV-1 epidemic in the country
(Ndung’u et al., 2000; Novitsky et al., 1999, 2002), with
sporadic detection of rare recombinants (Novitsky et al., 2000).
However, in other high-prevalence countries, particularly in
east Africa, the epidemic has rapidly evolved in recent years
with introduction and expansion of new subtypes or of
circulating recombinant forms (Hoelscher et al., 2002; Kou-
linska et al., 2001; Renjifo et al., 1998; Yang et al., 2004;
Yirrell et al., 2002). We investigated whether any such change
could be observed at a later stage of the epidemic in Botswana.
Phylogenetic analyses showed that sequences from samples
obtained in 2003 clustered with subtype C references (Fig. 1).
The 2003 sequences were scattered across the subtype C
branch and were not distinguished phylogenetically from
sequences isolated between 1996 and 2000 in Botswana.
Although the near full-length genome analysis allowed us to
identify intrasubtype lineages within HIV-1C, analysis of viral
sequences at the gene or partial gene level resulted in fewer
lineages supported by significant bootstrap values, demonstrat-
Table 3
Coreceptor usage characterization of the HIV-1C isolatesa
Sample ID Highest p24 antigen (pg/ml) in culture supernatant in U87 cells over 10-day period of culture
U87.CD4 U87.CD4.CCR1 U87.CD4.CCR2(b) U87.CD4.CCR3 U87.CD4.CXCR4 U87.CD4.CCR5
96BW.010 0 0 0 0 7 4,524,800
96BW.013 0 0 0 0 0 2,866,600
96BW.014 14 10 0 0 38 631,850
96BW.0502 18 9 33 26 931 166,430
96BW.1210 4 0 0 14 271 785,490
96BW.15B03 0 0 0 0 27 16,291
96BW06.J4 0 0 0 0 0 2,622,400
96BW11.06 0 0 20 0 0 3,694,100
96BW17A09 13 0 0 26 617,300 41,749
96BWMO1.5 24 27 0 0 831 2,473,500
96BWMO3.2 5 59 0 0 1544 525,290
03BW.0856 0 0 0 0 0 1,410,530
03BW.0868 0 0 0 0 10 1,410,530
03BW.0900 0 0 0 0 314 122,570
03BW.0949 0 0 0 0 0 67,890
03BW.1025 0 0 0 0 0 42,310
03BW.1075 0 0 0 0 0 113,125
03BW.1102 0 0 0 0 116,125 80,497
03BW.1110 0 0 0 0 120,000 8952
03BW.1133 0 0 13 0 0 256,864
03BW.1718 0 0 0 0 0 1,321,200
03BW.1787 0 0 0 0 0 14,637
03BW.1790 0 0 0 0 0 751,470
03BW.1796 0 0 0 0 0 127,700
03BW.4437 2 7 14 7 79 3,082,100
03BW.4473 0 0 8 0 22 68,694
03BW.4482 0 0 0 0 0 0
03BW.6218 0 0 0 0 0 0
03BW.6270 0 0 0 0 2 2,712,600
03BW.6274 0 38 0 0 7844 973,000
03BW.6360 0 0 0 0 131 2,773,200
a 2000pg of p24 viral supernatants from PBMC co-cultures were used to infect U87.CD4 cells expressing different coreceptors. Cells were washed 3 times with
PBS after 24 h, and fresh growth medium was added. Infection was followed by quantification of the p24 core protein by ELISA. Half the medium was sampled and
replaced with fresh medium at days 4 and 7.
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(Novitsky et al., 2002). Consistent with this observation, only
8 out of 13 Botswana lineages (including 3 partial lineages)
were found in the current analysis of the region spanning 957
nucleotides of env. Five lineages that included 2 to 3 sequences
were confirmed by significant bootstrap values, namely,
lineages 5, 7, 9, 10, and 16 described in Novitsky et al.
(2002), while three more lineages (#3, #13, and # 15) included
partial sequences that were seen in the near full-length analysis.
Interestingly, two isolates from the 2003 set (03BW.1017 and
03BW.1103) formed a new lineage that was supported by a
bootstrap value of 96. Sequences 03BW.1008 and 03BW.1796
clustered within previously described lineages with high
bootstrap values, lineage 9 and 15, respectively. The pairwise
evolutionary distances were similar within the subsets of
1996–2000 (n = 54) and 2003 (n = 38) sequences with mean
values of 14.4% and 15.7%, respectively.
A number of sequence-based methods, mostly dependent on
V3 loop amino acids, are available for predicting coreceptor
usage for HIV-1 viruses. In order to determine if the generated
sequences from CXCR4-tropic viruses may have distinctive
features associated with this phenotype, V3 loop sequences
were aligned and are shown in Fig. 2. The two most commonlyused methods for predicting CXCR4 coreceptor usage are
(i) the presence of basic amino acids at positions 11 and 25
of the V3 loop (de Jong et al., 1992; Fouchier et al., 1995)
and (ii) an overall charge of the V3 loop equal to or greater
than +5 (Fouchier et al., 1992). Among the 3 viruses that
favored CXCR4 usage, 2 had typical CXCR4-like features.
96BW17A09 had an overall V3 charge of +7 and a basic
amino acid (arginine) residue at position 25. This sequence
also had an insertion of 2 amino acids just upstream of the
crown of the V3 loop. The V3 loop crown for this sample was
an atypical GRGQ, in contrast to the GPGQ sequence most
commonly encountered among subtype C. The overall V3 loop
charge for 03BW.1102 was +6, with a basic amino acid at
position 11. This sequence also had a subtype B-like GPGR
crown sequence. The V3 loop sequence of the 03BW.1110
sample lacked a basic amino acid at either position 11 or 25, had
an overall V3 charge of +4 and a typical GPGQ crown se-
quence. Samples 03BW.1110 and 03BW.1102 shared a basic
amino acid substitution. Sample 03BW.6274, which might be
classified as a weakly dualtropic phenotype because it used
CXCR4 inefficiently and showed low level syncytia induc-
tion in MT-2 cells, had an atypical GPGA V3 loop crown
and an overall V3 loop charge of less than +5 with no basic
T. Ndung’u et al. / Virology 347 (2006) 247–260252amino acid at either position 11 or 25. The CCR5-tropic
isolate 96BWMO1.5 had a basic amino acid at position 10, a
feature that was shared with the dualtropic 03BW.1102 and03BW.1110. Sample 03BW.6360 had a basic amino acid
(arginine) at position 28. All the other CCR5-utilizing viruses
from 1996 and 2003 had features that are associated with R5-
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V3 loop charge of less than +5, lacked basic amino acids at
position 11 or 25, and had the typical subtype C GPGQ crown
sequence. We could not generate coreceptor usage data for 28
out of 61 (45.9%) samples in this study. This was because
source PBMCs did not yield a viral isolate on co-culture (21 of
61, 34.4%) or growth in PBMC was so poor that we did not
have enough supernatant to infect coreceptor expressing cells (9
of 29, 31.03%). Among these viruses for which coreceptor
utilization determination was not done, 03BW.1081 had some
unusual features. It had a high V3 loop charge of +9, the crown
was an uncharacteristic GLRY, and there were other unusual
insertions throughout the V3 loop (Fig. 2). These features are
suggestive of CXCR4 tropism.
It seemed possible that viruses that used CXCR4 less
efficiently than CCR5 might have had admixtures of X4 within
a majority R5 population, with the PCR-based sequences
reflecting only the R5 population. In order to select for se-
quences predictive of CXCR4 usage, we passaged all the nine
isolates that replicated to above 100 pg/ml in the initial
U87.CD4.CXCR4 culture two additional times in U87.CD4.
CXCR4 (a total of three passages). We extracted and amplified
the DNA and analyzed the V3 sequences following selection.
Isolates 96BW17A09, 03BW.1110, and 03BW.1102 showed
robust replication in each passage, and their DNA could be
amplified from the third round passage cells. Some changes,
better predictive of CXCR4 phenotype, were noted (Fig. 2).
For 03BW.1102, the V3 loop sequence from the U87.CD4.
CXCR4 cells had an overall charge of +7 due to a substitution
of glutamate to glutamine at position 25. The isolate 03BW.
1110 from U87.CD4.CXCR4 cells had a dramatic change
compared to PBMC derived sequences—the overall V3 loop
charge increased from +4 to +7, with a serine to arginine sub-
stitution at position 11, a V3 loop crown change from GPGQ to
GPGR, and a change at position 25 from aspartate to glu-
tamine. The V3 loop sequence for 96BW17A09 remained
unchanged.
Recently, Jensen et al. (2003) have described a position-
specific scoring matrices (PSSM) method for predicting
coreceptor usage using V3 loop sequences. In order to test
the usefulness of PSSM in comparison with other commonly
used methods for efficiency in predicting coreceptor usage for
HIV-1C, we assembled available coreceptor characterized
subtype C sequences from our current study in Botswana, as
well as from South Africa (Cilliers et al., 2003), Malawi (Ping
et al., 1999), Zimbabwe (Johnston et al., 2003), and from
Ethiopia (Pollakis et al., 2004), and used the different
methodologies to analyze them (Table 4). The web-based tool
available at http://ubik.microslu.washington.edu/computing/
pssm/ was used for this analysis. Comparison of predictionFig. 1. Phylogenetic tree analysis of the HIV-1 sequences. The tree was generated by
and reliability of the branching pattern was estimated by bootstraping (bootstrap valu
analyzed region of HIV-1 env (957 nucleotides) corresponds to HXB2 positions from
were obtained from the HIV database at http://hiv-web.lanl.gov. All the Botswana
sequences from 1996 to 2000 and 38 sequences dated 2003. The HIV-1C lineages s
include fewer viral sequences than those for which near full-length genome analys
lineage formed by 03BW.1017 and 03BW.1103 isolates was supported by a bootstefficiency for different methodologies is summarized in Table
4. PSSM was able to accurately predict coreceptor usage for
151 of 159 (94.97%) of the R5-tropic HIV-1C sequences.
When we used the 11/25 rule, which looks for a basic amino
acid at either position 11 or 25, 156 of the 159 (98.11%) R5-
tropic V3 sequences were found to be correctly identified.
Using the overall charge of the V3 loop, the efficiency of
prediction dropped dramatically, with only 113 of 159
sequences (71.07%) being predicted as R5-tropic. In contrast,
for the X4-tropic sequences, PSSM correctly predicted 16 of
the available 28 (57.14%) sequences. Only 11 of 28 (39.29%)
X4 sequences had a basic amino acid at either position 11 or
25, and 24 of 28 (85.71%) samples had an overall V3 charge
equal to or greater than +5.
Based on the procedure described in Materials and methods,
positions 7, 8, 11, 15, 16, 18, 20, 25, 27, and 29 in the V3 loop
were found to have significantly different distributions of
amino acids among the R5 and non-R5 sequence sets, after
Bonferroni adjustment for the 38 tests (all had P value
0.001). By the less stringent false discovery rate method of
controlling false positives, all positions with P value 0.027
were significant, which included the above 10 positions plus
sites 6, 9, 12, 13, 22, 24, and 31. The 17 significant positions
are indicated in Fig. 3.
Discussion
In this study, we have attempted viral isolation from PBMCs
and plasma samples obtained in 2003 from 42 HIV-1-infected
individuals from Botswana. Twenty-nine viral isolates were
obtained from the 42 samples, which is a viral isolation success
rate of 69.0%. Eleven viral isolates obtained in 1996 from HIV-
infected persons from Botswana were also included in this
study. These isolates were obtained by co-culturing with
PBMCs from anonymous donors from North America. A
direct comparison of the viral isolation success rates and
replication kinetics between the 2003 and 1996 sample sets is
complicated by the different culture conditions used to isolate
virus for the two sample sets and by the fact that viral load and
CD4 cell counts were not available for the 1996 samples.
Although only surprisingly few studies have systematically
examined the ease of viral isolation of HIV-1 from diverse
human populations at different stages of HIV infection and
disease, we find that our success rate is well within the range of
39% to 98% previously reported for Ugandan, Brazilian, Thai,
Rwandese, and North American populations (Burke et al.,
1990; Ichimura et al., 1994; Rubsamen-Waigmann et al.,
1994). However, it is worth noting that, although the isolation
rate appears to be within the range observed in other studies, a
significant proportion of the 2003 viral isolates studiedthe neighbor-joining method. Corrections were made for multiple substitutions,
es higher than 80 were considered significant and are shown in the figure). The
6858 to 7815. The reference sequences for different HIV-1 groups and subtypes
sequences clustered with subtype C reference sequences, including 54 viral
upported by significant bootstrap values are shown. Lineages #3, #13, and #15
is was previously performed and are shown with asterisks. A potentially new
rap value of 96.
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whether this is a property attributable to the subtype C viruses
or to donor PBMCs used in the isolation experiments. OtherFig. 2. Amino acid alignment of the V3 loop sequences of the Botswana
sequences. The alignment of all available sequences from Botswana was done
using ClustalX version 1.81. Gaps were introduced to maintain alignment and
avoid frameshifts where possible. Dots under the consensus sequences indicate
deletions and a dash represents conserved residues. For the dualtropic
sequences, both the sequences obtained directly from patient PBMC and
sequence obtained from third-passage U87.CD4.CXCR4 cells (marked with
asterisks) are shown. Sample 03BW.6274 (highlighted) was unique in that
although the virus showed weak CXCR4 tropism in initial U87.CD4.CXCR4
culture, it failed to replicate upon passage in these cells. The isolate induced
mild syncytia in MT-2 cells.factors that could result in differences in viral replication
include the percentages of CD4+ T cells in each PBMC culture,
the presence of CD8+ cells in cultures, which can suppress
HIV replication (and inhibit isolation), the presence of
inhibitory chemokines or cytokines, and other factors. The
possible contribution of these factors was beyond the scope of
this study. Furthermore, differences in CCR5 expression levels
as well as CCR5 cellular density are factors known to affect the
efficiency of R5 virus replication (Lin et al., 2002). Host
factors not withstanding, in light of reports suggesting that
HIV-1C may replicate poorly in CD4+ T lymphocytes (Pollakis
et al., 2004) and monocyte-derived macrophages (Bjorndal et
al., 1999), our study further adds to the need for a
comprehensive analysis of replication kinetics and fitness of
diverse HIV-1 strains in different host cell types and cellular
environments.
Contrary to reports from elsewhere of emerging CXCR4-
tropic HIV-1C isolates, we did not identify a single isolate that
was only tropic for CXCR4 from our study population. Three
isolates were clearly dualtropic, and they used CXCR4 more
efficiently in our assay than they did CCR5. All the other
isolates showed either inefficient replication or no replication
in U87.CD4.CXCR4 cells. We did not find usage of
coreceptors other than CCR5 and CXCR4 by HIV-1C isolates.
It is important to point out that our study population had not
received antiretroviral drugs, while in at least one report that
observed high frequency of HIV-1C X4 variants, the study
population had received antiretroviral drug treatment (Johnston
et al., 2003). Further studies of viral phenotype changes may be
necessary as antiretroviral drug access becomes widespread in
heavily affected regions.
The results here reinforce the observations that usage of
coreceptors other than CCR5 by HIV-1C is rare and may also
suggest that, even with an evolution towards X4-tropism, most
HIV-1C viruses are constrained to maintain CCR5 tropism. We
clearly do not know the biological properties underlying low
frequency coreceptor switch for this subtype, but a structural
constraint within subtype C envelope may be responsible. One
may also speculate that there is low or reduced cellular
expression of the CXCR4 chemokine receptor in a sub-Saharan
African population such as Botswana’s, where HIV-1C
predominates, resulting in limited cellular targets for X4
variants. However, we have preliminary evidence that CXCR4
expression is higher than CCR5 expression in Botswana,
suggesting that CXCR4 expression is not the limiting factor for
HIV-1C coreceptor switch.,
Table 4
V3 loop-based methods for predicting coreceptor usagea
Method Reference(s) Description % of R5 subtype C
sequences correctly
predicted (n = 159)
% of X4 subtype C
sequences correctly
predicted (n = 28)
11/25 (de Jong et al., 1992;
Fouchier et al., 1995)
Presence of basic amino acid at
either position 11 or 25 of the V3 loop
98.11% 39.29%
Overall V3 loop charge (Fouchier et al., 1992) Charge  +5 predicts X4/si phenotype,
< +5 predicts R5/NSI phenotype
71.07% 85.71%
PSSM score method (Jensen et al., 2003) High PSSM score predicts X4 usage,
low score predicts R5 usage
94.97% 57.14%
a A total of 159 HIV-1 subtype C sequences from Botswana, Malawi, Zimbabwe, South Africa, and Ethiopia with documented coreceptor usage were included in
analysis.
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sequences of HIV-1C and particularly the efficiency of
coreceptor usage prediction based on envelope V3 loop
sequence. We found that, while the traditional method of
looking for a basic amino acid at position 11 or 25 is very
efficient for identifying CCR5 tropic sequences, it performed
poorly in identifying CXCR4 variants (98% versus 39%) for
subtype C viruses. Similarly, the newly described PSSM
methodology using the subtype B algorithm was efficient in
identifying R5 variants but not X4 variants (95% versus 57%)
of HIV-1C. The overall V3 loop charge method was the best
for predicting X4 usage for subtype C sequences (86%), but itFig. 3. Amino acid alignment of the HIV-1 subtype C V3 loop sequences with docum
et al., 2003). Amino acid frequencies at different positions of the V3 loop are in
dualtropic/X4 sequences are indicated.did not perform as well for R5 tropic sequence prediction
(71%). It should be noted that these methodologies were
principally designed for subtype B sequences, and our work
suggests that the methods may need to be adjusted and
optimized for analysis of HIV-1 subtype C and other subtypes
which form the bulk of the HIV-1 pandemic. In particular,
comparison of V3 loop sequences by the amino acids at the 17
‘‘signature’’ positions identified in this study may be useful for
predicting R5 versus non-R5 phenotype for subtype C. These
positions may serve as important clues for guiding the design
of mutagenesis studies to study genetic determinants of
coreceptor utilization and switching.ented coreceptor usage from current and previously published studies (Cilliers
dicated. Positions showing significant frequency differences between R5 and
T. Ndung’u et al. / Virology 347 (2006) 247–260256Over the last several years, there has been an increasing
body of evidence to suggest that HIV-1C is unique in its
coreceptor usage and replication kinetics in diverse cell types. It
has been difficult, however, to put together all the studies on
HIV-1C and come up with an overriding theme on the biology
of HIV-1 subtype C in vitro or the clinical outcome of infection
in its human host, relative to other subtypes. On the one hand, it
is now well established that the use of the chemokine receptor
CXCR4 by HIV-1C is very rare, in contrast to subtype B
viruses where the use of CXCR4 is common particularly in late
stages of clinical disease. The scarcity of X4 variants among
HIV-1C raises questions of whether subtype C infections are
associated with delayed progression and/or a less aggressive
disease course since appearance of X4 variants has been
associated with faster disease progression or clinical deteriora-
tion of AIDS patients (Connor et al., 1997; Koot et al., 1992;
Richman and Bozzette, 1994; Tersmette et al., 1989b).
However, when normalized for CD4 cell counts, plasma viral
loads for people infected with HIV-1C are as high as or higher
than for other subtypes. When HIV-1C R5 variants are
compared to their subtype B counterparts, they appear to
replicate less efficiently, in macrophages and PBMCs but not in
dendritic and Langerhans cells (Ball et al., 2003; Pollakis et al.,
2004). It has therefore been speculated that HIV-1C is less fit
and may have an attenuated phenotype, resulting possibly in a
longer disease-free state for infected persons, but with
sufficiently high viral loads to allow for viral transmission.
Although this is an attractive model of how HIV-1C may have
spread to become the predominant subtype in the pandemic,
other hypotheses exist. For example, duplication of the NF-nB
enhancer element in the LTR region of HIV-1C has been
associated with increased responsiveness to cellular proteins
and proinflammatory cytokines (Jeeninga et al., 2000; Montano
et al., 1997, 2000; Naghavi et al., 1999), and this has therefore
led to speculation that HIV-1C may be associated with
increased replicative capacity, increased viral load, and
therefore increased odds of transmission and epidemic spread.
The situation is unlikely to be this simple; further studies have
shown that the influence of HIV-1 LTR on replication is host-
cell-dependent and is influenced by the cellular environment
(van Opijnen et al., 2004). Additionally, interpretation of
replication data is complicated by the fact that cellular factors
that drive viral transcription may have varied and apparently
opposing effects. The effect of TNF-a is a good example: while
TNF-a may preferentially upregulate HIV-1C replication by
transcriptional activation via the duplicated NF-nB enhancer,
this cytokine also downregulates the CCR5 chemokine receptor
(Lane et al., 1999), the main coreceptor for HIV-1C isolates,
leaving unanswered questions about what the overall effect of
this cytokine might be in a predominantly subtype C epidemic
such as the one raging in southern Africa.
In conclusion, we have generated HIV-1C viral isolates
from individuals at different stages of HIV-1C infection and
studied the isolates’ use of different chemokine receptors for
entry into target cells. We did not detect any changes towards a
higher frequency of CXCR4-tropism as the epidemic has
become more established in Botswana. Further studies areneeded to understand genetic changes other than coreceptor
usage switch, such as increased replicative capacity, that may
be associated with HIV-1C disease progression since this
phenomenon has been observed in HIV-1B infections (Camp-
bell et al., 2003). Analysis of V3 loop sequences in this study
also highlighted the limitations of the available methods for
predicting coreceptor usage for HIV-1 isolates. Our study
provides preliminary data for comparison with other studies. In
view of the importance of the HIV-1 envelope in determining
viral fitness, and as a target in both prophylactic and
therapeutic interventions such as vaccines and antiviral agents,
more work will be needed to address potential differences in
this gene between subtypes and to understand the evolution of
the subtypes that predominate in high-prevalence and incidence
regions. Genetic determinants of viral fitness outside of the env
gene will also need to be investigated.
Materials and methods
Sample testing
HIV testing, sample collection, PBMC isolation, and the
relevant study information for the 1996 samples used in this
study were described previously (Ndung’u et al., 2000;
Novitsky et al., 2001). For the 2003 samples, sample collection
and HIV testing were done as described for the previous
samples. CD4 cells were enumerated using the BD Multitest kit
(CD4/CD3/CD8/CD45) on a four-parameter FACSCalibur
flow cytometer (Becton Dickinson, Franklin Lakes, New
Jersey, USA). Viral load was determined using the automated
COBAS Amplicor/Ampli Prep HIV-1 Monitor Test V1.5
(Roche Molecular Systems Inc., Branchburg, New Jersey,
USA).
Viral isolation
PBMCs were separated by density-gradient centrifugation
on Lymphocyte Separation Medium (Organon Teknika, Corp.,
Durham, NC) or Ficoll-Paque (Amersham Biosciences,
Uppsala, Sweden). 5  106 PBMCs from three anonymous
HIV-negative donors were mixed and pre-stimulated by
culturing in RPMI 1640 supplemented with 10% FBS, 5 Ag/
ml phytohemagglutinin (Sigma, St. Louis, MO), and 20 U/ml
of interleukin-2 (Becton Dickinson Labware, Bedford, MA) for
72 h prior to infection in a T-25 flask. To isolate virus, 2  106
PBMCs from an HIV-positive individual were co-cultured with
the stimulated HIV-negative PBMCs in the presence of 20 U/
ml of interleukin-2. Cultures were sampled and fed with 50%
of replacement of the total culture volume at days 4, 7, 10, and
14. If there was no evidence of viral growth by day 14, cultures
were kept up to day 21, with additional media replacement at
day 18. Viral growth was monitored by quantification of p24
using the Vironostika HIV-1 Antigen Microelisa system
(Biomerieux, Boxtel, Netherlands).
For the 2003 samples, there were 5 cases where PBMCs did
not yield virus and plasma was available for viral isolation.
Viral isolation was therefore attempted from plasma for those 5
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and 03BW.1081). Virus isolation from plasma was attempted
using the method described by Cilliers et al. (2003). Briefly,
donor PBMCs were pre-stimulated with IL-2 and PHA and
then incubated overnight with 500 Al HIV-positive plasma.
After 24 h, the PBMCs were washed three times with PBS and
fed with fresh medium. By using this methodology, 2 isolates
were generated (Table 1).
Determination of coreceptor usage
U87.CD4 cells were obtained from the NIH AIDS Research
and Reference Reagent Program (Rockville, MD). U87.CD4
cells expressing chemokine receptors CCR1, CCR2b, CCR3,
CXCR4, or CCR5 were maintained in Dulbecco’s modified
eagle’s medium (DMEM) supplemented with 15% FBS, 1 Ag/
ml puromycin, and 300 Ag/ml G418. U87.CD4 cells were
cultured in the same medium but without puromycin. All the
U87.CD4 cells were cultured in 6-well flat bottom plates in
2000 Al total volume of culture medium. PBMC tissue culture
supernatants corresponding to 2000 pg of p24 antigen per well
were used to infect U87.CD4 glioma cells that express different
chemokine receptors. Sampling was done by replacing half of
the culture medium at days 4 and 7.
Three proviral clones were used as positive controls—the
CXCR4 tropic subtype B clone HXB2RU3, which is a
derivative of HXB2 that has intact vpu, vpr, and nef genes
(Ratner et al., 1987; Yu et al., 1992), HXB2RU3CI, which is
equivalent to HXB2RU3 except for the V3 loop, which has
been exchanged with a CCR5-tropic V3 loop (Trujillo et al.,
1996; Wang et al., 1998), and MJ4, a CCR5-tropic subtype C
clone (Ndung’u et al., 2001). Subconfluent 293T cells,
propagated in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% FBS, were transfected with 8 Ag of
plasmid DNA using 20 Al Lipofectamine 2000 transfection
reagent (Invitrogen). Seventy-two hours post-transfection,
culture supernatants were harvested and filtered through 0.45
Am-pore-size filter units (Nalgene, Rochester, NY) and HIV-1
virions were quantified by p24 antigen ELISA (Vironostika,
Boston, MA). Equivalent amounts of virus (as determined by
amount of p24 antigen in culture supernatant) were used to
infect duplicate wells of 2  105 U87.CD4 glioma cells with
or without chemokine receptors. Twenty-four hours post-
infection, cells were washed three times with phosphate-
buffered saline (PBS), and fresh medium was then added.
Infection of the target cells was monitored for 10 days by p24
ELISA.
Passage in U87.CD4.CXCR4 cells
All viral isolates that replicated to at least 100 pg/ml of p24
antigen in the initial U87.CD4.CXCR4 culture were passaged
for 2 more rounds in fresh U87.CD4.CXCR4 cells (a total of
three passages). At each round of passage, growth was
monitored by p24 antigen production. At the end of the culture
period, third round passage cells were lysed, DNA extracted,
and PCR amplification of the HIV-1 env gene done.Propagation in the MT-2 cell line
The MT-2 cell line was originally obtained through the
AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH, Dr. Douglas Richman, and was also the
kind donation of Dr. Lynn Morris of the National Institute of
Communicable Diseases (Johannesburg, South Africa). The
cells were propagated in RPMI 1640 medium supplemented
with 10% FBS in a T-25 flask. Each flask of 2  106 cells was
infected with PBMC tissue culture supernatants corresponding
to 2000 pg of p24 antigen. Cultures were sampled and fed with
50% of replacement of the total culture volume at days 4, 7, 10,
and 14 and cultured for a total of 21 days. The flasks were also
observed under the microscope for evidence of syncytia
induction. Viral growth was also monitored by quantification
of p24 antigen.
DNA extraction and envelope PCR amplification
Genomic DNAwas extracted directly from patients’ PBMCs,
PBMC co-cultures, or U87.CD4.CXCR4 cells using the
QIAamp Blood kit (Qiagen, Chatsworth, CA). We used the
Amplitaq Gold PCR kit (Roche Molecular Systems, Branch-
burg, New Jersey) to amplify a 957 basepair C2–C5 fragment of
the env gene. A nested PCR reaction protocol was used. In the
first round reaction, the forward primers were vpu157 (GCA-
GAAGACAGTGGCAATGA) and vpu232 (TGCTCCTT-
GGGATATTGATGA), while the reverse primers were p130
(TTGATGCCCCAGACTGTGAGTT) and p131 (AGCCAG-
GACTCTTGCCTGGAGCT). Four primers were used to
minimize non-amplification due to primer– template mis-
matches. Four microliters of the first round reaction product
was subjected to a second round of amplification, with the
primers Bstq2+ (CCAATTCCTATACATTATTGTGC) and
1556 (CCATAGTGCTTCCTGCTGCTCCTAAGAACCCAA).
Ten picomoles of each primer was used per PCR reaction. The
cycling conditions for both amplifications consisted of initial
activation at 95 -C for 10 min followed by 39 cycles of 94 -C for
1 min, 52 -C for 1 min, and 72 -C for 3 min. There was a final
extension at 72 -C for 10 min. In cases where DNA was
unavailable, amplification was attempted from plasma-extracted
RNA, when available. RNAwas amplified using the Titan One
Tube RT-PCR kit (RocheDiagnostics Corporation, Indianapolis,
IN, USA). Cycling conditions for the RT-PCRwere as described
above but with an initial reverse transcription step at 50 -C for 30
min. The PCR products were visualized by running a 1% agarose
gel, and they were then purified using the Qiaquick PCR
purification kit (Qiagen).
Sequencing and sequence analysis
The PCR product was directly sequenced on both strands
using Big Dye chemistry on an ABI Prism 3100 Genetic
Analyzer (Applied Biosystems, Foster City, California, USA).
Individual contiguous sequences were assembled and edited
using the Sequencher software program (Gene Codes Corpo-
ration, Ann Arbor, Michigan). Multiple sequence alignment
T. Ndung’u et al. / Virology 347 (2006) 247–260258was carried out using ClustalX version 1.81. Alignment was
manually adjusted using BioEdit. The pairwise distances of
nucleotide alignment were computed by DNADist with the
Kimura two-parameter model. The neighbor-joining tree and
bootstrap values were generated using TreeCon version 1.3b.
To search for ‘‘signature positions’’ that distinguish R5 from
non-R5 V3 loop sequences, we assembled HIV-1C V3 loop
amino acid sequences with documented coreceptor usage from
current and previously published studies (Cilliers et al., 2003;
Johnston et al., 2003; Ping et al., 1999; Pollakis et al., 2004).
Each position in the V3 loop was examined for possible
differences in the distribution of amino acid frequencies among
the 159 R5 sequences and the 28 non-R5 sequences. The
difference in amino acid distributions at each position i was
measured using a Kullback–Leibler statistic, defined as
KL ið Þ ¼ Aaa f1 i; aað Þlog I f2 i; aað Þ > 0ð Þ f1 i; aað Þ=f2 i; aað Þ½ f
þ I f2 i; aað Þ ¼ 0ð Þ f1 i; aað Þ þ 1=n1ð Þ= 1=n2ð Þ½ g;
where the sum aa is over the 20 amino acids plus a gap character,
f1(i, aa) is the fraction of the 28 non-R5 sequences with amino
acid aa, f2(i, aa) is the fraction of the 159 R5 sequences
with amino acid aa, n1 = 28, n2 = 159, and I( f2(i, aa) > 0) is
1 if f2(i, aa) = 1 and 0 otherwise. The statistic KL(i) was
proposed by Wu et al. (2001) as a measurement of sequence
dissimilarity and is similar to the entropy statistic (Yusim et al.,
2002).
A permutation procedure was used for computing P values
for each of the 38 positions. Permuted datasets were generated
by randomly dividing the pooled set of 187 V3 loop sequences
into two sequence sets, of sizes 28 and 159 sequences. Ten
thousand permuted datasets were generated, and, for each
dataset, a 2-sided P value for each position i was computed as
Ni/10,000, where Ni is the number of the KL(i) statistics
computed based on permuted datasets that equaled or exceeded
the value of KL(i) computed based on the real dataset. To avoid
a high rate of false positive results, it is necessary to account
for the fact that 38 tests were performed. Two methods were
used to correct for the multiple tests; first, the Bonferroni
method was used, according to which positions with P value <
0.05/38 = 0.00132 were deemed significant; and second, the
false discovery rate method was used (Benjamini and Hoch-
berg, 1995), which determines the set of significant positions
such that fewer than 5% of these significant positions are
expected to be ‘‘false discoveries’’ (i.e., erroneous findings).
The statistical procedure was implemented in Fortran 90.
Genebank accession numbers
New sequences described in this study are available under
GenBank accession nos. AY887852–AY887892.
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